Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +48.38%
#3 龙虾 (Lobster) 龙虾 (Lobster) +22.75%
#4 OriginTrail OriginTrail +21.47%
#5 Non-Playable Coin Non-Playable Coin +21.04%
#6 Pons Pons +19.40%
#7 ApeX ApeX +19.29%
#8 DigiByte DigiByte +18.65%
#9 Zora Zora +18.63%
#10 Morpho Morpho +17.03%
Coin of the day
Smilek to the Bank Smilek to the Bank
設定
言語
日本
通貨
USD
テーマ
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
株式のランク #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
株価
$50.82
最終同期: 2026-08-11
時価総額
$102.09M
変化（1日）
1.90%
変化（1年）
-
国
US
取引 Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

カテゴリー

Healthcare
Hemab Therapeutics Holdings, Inc. Common Stock（COAG）の利益
2026 時点の利益 TTM: 0
Hemab Therapeutics Holdings, Inc. Common Stock の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Hemab Therapeutics Holdings, Inc. Common Stock の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH